Caroline Seymour

Early trials are exploring the benefit of chimeric antigen receptor T-cell therapy in advanced renal cell carcinoma.

Amivantamab-vmjw with lazertinib showed positive survival results vs osimertinib as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

Tisotumab vedotin-tftv improved survival in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.

Modest but durable antitumor activity was observed with sacituzumab govitecan-hziy in the treatment of patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.

The BEAMION Lung-1 trial of zongertinib in HER2–mutant solid tumors is advancing to phase 1b following encouraging preliminary results.

Responses to BI 764532 in patient siwth DLL3-positive small cell lung cancer appear to be durable and are ongoing in the dose optimization portion of a phase 1 study.

Relapsed/refractory DLBCL is associated with poor prognosis, but preclinical data suggest that adding rituximab to CD19-directed therapy such as loncastuximab tesirine may extend the duration of disease control.

There was no difference in outcomes observed with intensive vs non-intensive consolidation chemotherapy regimens before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.

REGN5459 led to positive responses among patients with multiple myeloma, according to findings from a first-in-human phase 1/2 trial.

In the phase 2 KEYNOTE-942 trial, the 18-month distant metastasis-free survival rate was 91.8% with mRNA-4157 plus pembrolizumab vs 76.8% with pembrolizumab alone.

Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.

Treatment with lisocabtagene maraleucel elicited encouraging responses and met the primary end point of the TRANSCEND CLL 004 trial in patients with relapsed/refractory CLL/SLL.

Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.

New data show the promise for use of tovorafenib to reduce pre-treated pediatric patients with a low-grade glioma.

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

News results from. the phase 3 AEGEAN trial further support the use of PD-1/PD-L1 inhibitors in the neoadjuvant and adjuvant setting for patients with non–small cell lung cancer.

Phase 2 findings support a phase 3 investigation of neoadjuvant SHR-1701 as combination therapy for untreated stage III unresectable non–small cell lung cancer.

In 8 patients with various hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors, Orca-T led to a 100% survival rate.

Findings from the phase 2 DALY II USA trial showed that the 28-day objective response rate was 78% with freshly administered zamtocabtagene autoleucel, exceeding the prespecified efficacy threshold for interim analysis.

The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.

In non–small cell lung cancer, EGFR mutations, MET exon 14 skipping mutations, and HER2 mutations are common mutation for which directed therapies are available.

The combination of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is moving into the frontline setting for patients with diffuse large B-cell lymphoma.

A more severe symptom burden was seen in patients with isolated thrombocytopenia vs those with isolated anemia, according to findings from the phase 3 PERSIST-1 and PAC203 trials in myelofibrosis.

Adding magrolimab to azacytidine and venetoclax led to a rate of high responses in high-risk de novo and secondary acute myeloid leukemia.

Among premenopausal patients, the addition of everolimus to endocrine therapy improved iDFS and OS, which is hypothesis generating, said Mariana Chavez-MacGregor, MD.

Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.

Patients with more than 2 tertiary lymphoid structures, high Ki-67, and PD-1 positivity had high response rates to nivolumab plus ipilimumab.

The rate of 2-year overall survival was nearly doubled with atezolizumab vs vinorelbine or gemcitabine in advanced platinum-ineligible non–small cell lung cancer.